Delphia Therapeutics has appointed David Kerstein as Chief Medical Officer (CMO). Delphia is a biopharmaceutical company pioneering an innovative new area of cancer biology – activation lethality – ...

GSK has announced that it will be acquiring Boston Pharmaceuticals’ phase 3-ready liver disease candidate in a deal worth up to $2bn. Efimosfermin alfa is an investigational drug in clinical ...

For pharma brands, AI visibility is no longer just a digital question, it is fast becoming a brand strategy imperative ...

UK market access needs the right conditions nationally, along with subnational investment and delivery locally ...

The National Institute for Health and Care Excellence (NICE) has recommended Genmab UK’s Tivdak (tisotumab vedotin) for ...

In the fast-paced environment of clinical medicine, it is easy to focus solely on data and outcomes. However, as Dr. Toyin ...

Eli Lilly is to acquire LimmaTech Biologics and Vaccine Company. Along with its acquisition of Curevo, the companies will ...

The “problem” in healthcare comms is rarely what you say, it’s whether people can act on it. This article explains how we ...

This year, we welcome Simon Bates as the new Chair of the judging panel, someone who has been a judge and steering group ...

Over the last decade, the trial landscape has been undergoing reforms to become more focused on enrolling a diverse ...

Engaging healthcare professionals (HCPs) remains a persistent challenge for pharmaceutical companies, not because of a lack ...

Eli Lilly has announced that it will acquire Curevo to expand the company’s research and development efforts into infectious ...